Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.11 USD

76.11
1,035,772

-0.19 (-0.25%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $76.14 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold on to Quest Diagnostics Stock Now

by Zacks Equity Research

Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.

Zacks Equity Research

Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

by Zacks Equity Research

The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

Zacks Equity Research

Haemonetics Grows on Strong Plasma, Hemostasis Management

by Zacks Equity Research

Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

Zacks Equity Research

Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high in GNC Holdings (GNC), thanks to solid prospects.

Zacks Equity Research

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

by Zacks Equity Research

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Zacks Equity Research

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

by Zacks Equity Research

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

Zacks Equity Research

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

by Zacks Equity Research

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Zacks Equity Research

Align Technology Inks Distribution Deal With Zimmer Biomet

by Zacks Equity Research

This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.

Zacks Equity Research

Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ

by Zacks Equity Research

Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.

Zacks Equity Research

Intersect ENT Rides on Innovation Amid Pricing Concerns

by Zacks Equity Research

The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.

Zacks Equity Research

Medtronic Collaborates With Novo Nordisk for Diabetes Care

by Zacks Equity Research

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Zacks Equity Research

Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well

by Zacks Equity Research

The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.

Zacks Equity Research

Haemonetics (HAE) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.

Zacks Equity Research

LabCorp's Covance Launches Laboratory Data Management Service

by Zacks Equity Research

LabCorp (LH) expands service portfolio through Covance's data management portal.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for August 29th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Zacks Equity Research

AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm

by Zacks Equity Research

AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.

Zacks Equity Research

Allscripts Inks Deal With Apple for Electronic Health Record

by Zacks Equity Research

Allscripts (MDRX) is working toward providing compact health records.

Zacks Equity Research

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Zacks Equity Research

Omnicell's Autonomous Pharmacy to Boost Medication Management

by Zacks Equity Research

Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.

Zacks Equity Research

EYE vs. HAE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EYE vs. HAE: Which Stock Is the Better Value Option?

Zacks Equity Research

Baxter's PrisMax Adopted by Hamilton Health Care System

by Zacks Equity Research

Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.

Zacks Equity Research

Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up

by Zacks Equity Research

Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.